XC001
Sponsors
Xylocor Therapeutics Inc., XyloCor Therapeutics, Inc.
Conditions
Chronic angina and left ventricular dysfunction due to coronary artery disease that is considered high risk for incomplete revascularization via coronary artery bypass graftingCoronary Artery DiseaseCoronary Artery Disease (CAD)Refractory AnginaRefractory angina due to obstructive coronary artery disease
Phase 2
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RecruitingNCT07048808
Start: 2025-07-08End: 2027-12-30Target: 106Updated: 2026-09-11
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
Not yet recruitingNCT07118449
Start: 2025-08-27End: 2027-06-30Target: 116Updated: 2025-08-12
Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety (EXACT-2 Trial)
Not yet recruitingCTIS2024-514874-36-01
Target: 84Updated: 2026-01-23
A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization
Not yet recruitingCTIS2025-521325-33-00
Target: 90Updated: 2025-11-15